Related Experiment Video
Updated: May 27, 2026
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Lipophilic Pt(II) complexes with selective efficacy against cisplatin-resistant testicular cancer cells
Bernhard Biersack1, Andrea Dietrich, Miroslava Zoldakova
1Organic Chemistry Laboratory, University Bayreuth, Bayreuth, Germany.
Abstract:
A series of dichloridoplatinum(II) complexes with selective and high cytotoxicity [IC(90)(96h)≤3 μM] against cisplatin-resistant 1411HP testicular cancer cells were identified. They bear stationary 6-aminomethylnicotinate or 2,4-diaminobutyrate ligands esterified with lipophilic terpenyl residues, i.e., (-)/(+)-menthyl, (+)-cedrenyl, (-)-menthoxypropyl, or with a decyl-tethered 1,1,2-triphenylethene. They accumulated to a larger extent in 1411HP cells than in cells of the cisplatin-sensitive H12.1 germ cell tumour. Their mechanism of apoptosis induction differed from that of cisplatin by being independent of p53 and of caspase-3 activation and by an early loss of the mitochondrial membrane potential. The new complexes are promising candidates for the treatment of cisplatin-resistant testicular tumours.
Insights
New platinum(II) complexes show high efficacy against cisplatin-resistant testicular cancer cells. These compounds induce apoptosis through a novel mechanism, offering promise for treating resistant tumors.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Cisplatin resistance is a major challenge in treating testicular germ cell tumors.
- Novel therapeutic strategies are needed to overcome cisplatin resistance.
Purpose of the Study:
- To identify novel dichloridoplatinum(II) complexes with potent activity against cisplatin-resistant testicular cancer cells.
- To elucidate the mechanism of action of these new complexes.
Main Methods:
- Synthesis and characterization of novel dichloridoplatinum(II) complexes.
- In vitro cytotoxicity assays using cisplatin-sensitive and resistant testicular cancer cell lines.
- Cellular uptake studies.
- Apoptosis induction pathway analysis, including p53, caspase-3, and mitochondrial membrane potential assessment.
Main Results:
- Several dichloridoplatinum(II) complexes exhibited high cytotoxicity (IC(90)(96h)≤3 μM) against cisplatin-resistant 1411HP cells.
- These complexes showed selective accumulation in resistant cells compared to sensitive cells.
- Apoptosis induction was independent of p53 and caspase-3 activation, with early mitochondrial membrane potential loss.
Conclusions:
- The novel platinum(II) complexes demonstrate significant potential for treating cisplatin-resistant testicular germ cell tumors.
- Their unique mechanism of action, distinct from cisplatin, warrants further investigation for therapeutic development.
